Metadata record for: Morphometrics of eight Chinese cavefish species

This dataset contains key characteristics about the data described in the Data Descriptor Morphometrics of eight Chinese cavefish species. Contents: 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format Versioning Note:Version 2 was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.</div

Morphometrics of eight Chinese cavefishes

This dataset provide information on eight species of Chinese cavefishes. Data showed here are the following: 1) ID_Collection (The specimen’s code in the ASIZB collection); 2)Family (The specimen’s family); 3) Genus (The specimen’s genus); 4)Species (The specimen’s species name); 5) Country(The country of specimen collection); 6) Province(The province of specimen collection); 7) County (The county of specimen collection); 8-9) Latitude and Longitude (Downgraded coordinates of collection localities); 10-11) Month and Year(The date of specimen collection); 12) Population(Code of each cavefish population); 13) Eye (Indicates if the eye is well Developed, Reduced or Absent); 14) Mouth_position (Indicates the position where the mouth opens:, Terminal, Subterminal, Inferior, Superior); 15) Caudal_fin_shape (Indicates the shape of the fish caudal fin: Rounded, Truncate, Emarginate, Forked, Lunate); 16-44) Measurement typology (The recorded measurements of cavefishes). Lengths are recorded in mm, while the area in mm2

Additional file 1 of Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses

Additional file 1: Table S1. Descriptive summary of datasets used in the study. Table S2. Genes of the 00982_1 subpathway. Table S3. Predictive power of published gene signatures. Figure S1. Dataset Search strategy in GEO database. Figure S2. Flow diagram of dataset selection strategies. Figure S3. Accumulative predictive abilities of signatures. Figure S4. Genes in the path:00982_1 subpathway. Figure S5. Collision classification for GSE57495 and GSE79668 datasets. Figure S6. Prognostic capacity of path:00982_1 signature for classical subtype. by Moffitt classification. Figure S7. Association of path:00982_1 subpathway with other pathways

CAR attenuates liver damage in I/R rats.

<p>(A) Representative images were taken from HE-stained liver sections (Upper panel: 40× magnification; lower panel: 400× magnification) from the sham, CAR, I/R and I/R+CAR groups. The above liver sections were assessed for histological scores. Values were expressed as mean ± SEM (n = 8). NS, no significant difference. ^*<i>P</i><0.05 compared to the sham group; ^#<i>P</i><0.05 compared to the I/R group.</p

CAR inhibits apoptosis of H/R BRL cells <i>in vitro</i>.

<p>The cells in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0104043#pone-0104043-g006" target="_blank">Figure 6</a> were further stained by Hoechst 33258. (B) Apoptotic cells were counted. Values were expressed as mean ± SEM (n = 8). ^**<i>P</i><0.001 compared to the control group; ^##<i>P</i><0.001 compared to the H/R group; ^$$<i>P</i><0.001 compared to the H/R+CAR group.</p

Detection of Akt and p-Akt expressions by western blot analysis.

<p>The lysates of liver tissues (A) and BRL cells (B) from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0104043#pone-0104043-g008" target="_blank">Figure 8</a> were further Western blotted to detect the expression of p-Akt and total Akt. Band density was measured and normalized to that of total Akt. Data were expressed by mean ± SEM (n = 8). NS, no significant difference. ^**<i>P</i><0.001 compared to the sham group or control cells; ^##<i>P</i><0.001 compared to the I/R group or H/R group; ^$<i>P</i><0.05 compared to the H/R+CAR group.</p

CAR restores on the viability of H/R BRL cells <i>in vitro</i>.

<p>Untreated BRL cells (control), BRL cells subjected to H/R hypoxia, and BRL cells subjected to H/R hypoxia and treated with different concentrations of CAR (0.3, 0.6, 1.2 or 2.4 mM) were analyzed for the viability. Values were expressed as mean ± SEM (n = 8). ^**<i>P</i><0.001 compared to the control group; ^#<i>P</i><0.05 and ^#<i>P</i><0.001 compared to the H/R group.</p

Car exhibits anti-oxidative activity in I/R rats.

<p>The hepatic levels of SOD (A), CAT (B), GSH (C) and MDA (D) were measured, and values were expressed as mean ± SEM (n = 8). NS, no significant difference. ^**<i>P</i><0.001 compared to the sham group; ^##<i>P</i><0.001 compared to the I/R group.</p

CAR reduces the serum levels of ALT and AST in I/R rats.

<p>The serum levels of ALT (A) and AST (B) were measured, and values were expressed as mean ± SEM (n = 8). NS, no significant difference. ^**<i>P</i><0.001 compared to the sham group; ^##<i>P</i><0.001 compared to the I/R group.</p

Inhibition of Akt enhances sorafenib-induced growth inhibition and apoptosis.

<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence or absence of perifosine (10 μM) for 48 h. (A) Cell viability (%) was then compared with the corresponding untreated cells. (B) The percentages of apoptotic cells (%) were measured by flow cytometry. Untransfected cells served as controls. C-D, HepG2 and Huh7 cells were transfected with control or Akt siRNA for 24 h and then incubated with 100 nM bufalin, 5 μM sorafenib, or a combination of the two drugs for 24 h. (C) Cell viability (%) was compared with control siRNA-transfected cells. (D) The percentages of apoptotic cells (%) were measured by flow cytometry. Untransfected cells served as controls. The data represent three independent experiments. “**” represents P<0.001.</p